The IDH mutation, on the other hand, causes the use of α-KG and NADPH to produce an oncometabolite, D-2-hydroxyglutarate (D2HG), which has a direct role in creating the G-CIMP phenotype and producing aberrant DNA methylation in gliomas. This evidence concerns the gene IDH1 and glioma.